Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial

Autor:	Arribas, José R1 joser.arribas@salud.madrid.org, Girard, Pierre-Marie2, Landman, Roland3, Pich, Judit4, Mallolas, Josep4, Martínez-Rebollar, María4, Zamora, Francisco X1, Estrada, Vicente5, Crespo, Manuel6, Podzamczer, Daniel7, Portilla, Joaquín8, Dronda, Fernando9, Iribarren, José A10, Domingo, Pere11, Pulido, Federico12, Montero, Marta13, Knobel, Hernando14, Cabié, André15, Weiss, Laurence16, Gatell, José M4
Zdroj:	Lancet Infectious Diseases. Jul2015, Vol. 15 Issue 7, p785-792. 8p.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu